Clinical trials: Pulmonary Hypertension (World Health Organization Group 3)
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
Two-Part Dose-Confirming Study of Pulsed Inhaled Nitric Oxide in Subjects With WHO Group 3 Pulmonary Hypertension Associated With COPD
This is a placebo-controlled, double-blind, parallel, randomized, two-part, dose-confirming clinical study characterizing the pharmacodynamic effects of pulsed iNO using the combination product, inhaled nitric oxide/INOpulse DS-C…
- Trial name
- NCT01728220
- Testing
- Inhaled NO delivered via INOpulse DS-C Device
- Where
- 43 sites in United States
- Volunteers
- 159 people
- Sponsor
- Bellerophon Pulse Technologies
Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3)
Nailfold Capillaroscopy in PH
Pulmonary hypertension (PH) is an uncommon condition and can often be difficult to diagnose. It means elevated blood pressure in the lungs which can rapidly lead to failure of the right side of the heart and is ultimately fatal.
- Conditions
- Pulmonary Arterial Hypertension (PAH) (WHO Group 1 PH), Pulmonary Hypertension (World Health Organization Group 3), Chronic Thromboembolic Pulmonary Hypertension
- Trial name
- NCT07768644
- Testing
- Standard of Care therapy
- Where
- United Kingdom
- Volunteers
- 60 people
- Sponsor
- University of Glasgow
Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease
3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF
The objective of this exploratory study is to examine the utility of high resolution computed tomography (HRCT) to measure changes in functional pulmonary imaging parameters as a function of short term a) iNO administration and…
- Conditions
- Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease, Idiopathic Pulmonary Fibrosis
- Trial name
- NCT02267655
- Testing
- inhaled Nitric Oxide - 30 mcg/kg IBW/hr, inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr, inhaled nitric oxide 75 mcg/kg IBW/hr
- Where
- Belgium
- Volunteers
- 8 people
- Sponsor
- Bellerophon
PAH, Pulmonary Hypertension
A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension
Study ROR-PH-303, ADVANCE EXTENSION, is an open-label extension (OLE) study for participants with WHO Group 1 PAH who have participated in another Phase 2 or Phase 3 study of ralinepag.
- Conditions
- PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension, Hypertension
- Trial name
- NCT03683186
- Testing
- Ralinepag
- Where
- 190 sites in United States, Argentina and 31 more
- Volunteers
- 1,000 people
- Sponsor
- United Therapeutics